Biocytogen (Beijing) Co., Ltd has announced the successful research and development of a fully-human nano antibody RenNano, following its previous achievements with RenMab and RenLite. The China-based Contract Research Organization (CRO) is now capable of developing fully-human monoclonal antibodies (mAbs), fully-human bispecific antibodies (BsAbs), and fully-human nano antibodies.
RenNano Profile
The nano antibody, featuring a small molecular weight and good permeability, can cross the blood-brain barrier, infiltrate tumors, and reach areas inaccessible to ordinary antibodies. Its CDR3 region is longer than that of ordinary antibodies, allowing it to target hidden epitopes of difficult targets such as GPCR. This capability is significant for addressing refractory diseases. Due to its simple structure and zero pairing, RenNano is suitable for modular assembly and easy to build dual/multiple antibodies and CAR-T therapies.
Development and Applications
After immunizing RenNano mice with various antigens, HCAb antibodies with diverse CDR3 sequences and rich recognition epitopes can be obtained. These antibodies bind antigens independent of light chains and exhibit high affinity at the nM level. Experiments have shown that RenNano has good biological function both in vitro and in vivo, highlighting its potential for therapeutic applications.-Fineline Info & Tech